Health care stocks declined Thursday afternoon with the NYSE Health Care Index shedding 0.7% and the Health Care Select Sector SPDR Fund (XLV) falling 1.2%.
The iShares Biotechnology ETF (IBB) dropped 1%.
In corporate news, Novo Nordisk (NVO) Chief Executive Officer Lars Fruergaard Jorgensen said the company will feel the impact of President Donald Trump's threatened tariffs despite its investments in the US, according to media reports. Novo shares declined 3.4%.
Plus Therapeutics (PSTV) shares surged 98% after it said Thursday that its Rhenium obisbemeda radiotherapy has been granted orphan drug designation by the US Food and Drug Administration for treating leptomeningeal metastases in lung cancer patients.
BridgeBio Pharma (BBIO) shares were falling past 6% after KKR Genetic Disorder disclosed the sale of 6 million BridgeBio shares in a regulatory filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。